Compare CODA & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | BNR |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | China |
| Employees | N/A | 667 |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.3M | 99.7M |
| IPO Year | 2007 | 2019 |
| Metric | CODA | BNR |
|---|---|---|
| Price | $10.08 | $9.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 58.3K | 5.8K |
| Earning Date | 06-15-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $20,316,161.00 | N/A |
| Revenue This Year | $18.28 | $111.65 |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | $43.70 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $7.80 | $6.79 |
| 52 Week High | $18.00 | $41.72 |
| Indicator | CODA | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 46.25 |
| Support Level | $9.85 | $8.83 |
| Resistance Level | $10.50 | $10.72 |
| Average True Range (ATR) | 0.32 | 0.76 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 33.02 | 18.86 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.